Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219303 · ClinicalTrials.gov registry record · NA
Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer
A NA study of Prostate Cancer (Adenocarcinoma), sponsored by Fox Chase Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT07219303: Recruiting NA study of Prostate Cancer (Adenocarcinoma), sponsored by Fox Chase Cancer Center.
NCT07219303 is a NA study of Prostate Cancer (Adenocarcinoma) that is actively recruiting participants, run by Fox Chase Cancer Center. The registered enrollment target is 80 participants, below the 124-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219303, a NA study of Prostate Cancer (Adenocarcinoma), is actively recruiting participants, sponsored by Fox Chase Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: * What is highest dose of adaptive SBRT without causing serious side effects? * Can adaptive SBRT more precisely targeting the prostate while reducing radiation exposure to nearby organs? * What side effects do participants experience during treatment, right after treatment, and over the five years post-treatment? * Can adaptive SBRT reduce urination-related side effects and support quality of life during and after treatment? Participants will: * Receive adaptive SBRT treatment every other day, for a total of 5 treatment sessions (called fractions). The full course of treatment typically takes 2 to 3 weeks. * Have a follow-up phone call about 6 weeks after treatment to check on side effects and overall wellbeing. * Visit the clinic for check-ups and tests: * At 90 days (about 3 months) after treatment * Then every 3 months for the first year * Then every 6 months after that
Conditions Studied
Interventions
- RADIATION adaptive stereotactic body radiation therapy (SBRT) with a SIB
Study Locations (1)
Pennsylvania
- Fox Chase Cancer Center - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2025-09-25 |
| Est. Completion | 2033-11-01 |
| Phase | NA |
What NCT07219303 shows while recruiting
NCT07219303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 124-participant average among 13 other Prostate Cancer (Adenocarcinoma) trials with a reported enrollment target (35% lower).
The record links to 1 condition, with Prostate Cancer (Adenocarcinoma) appearing as the primary indexed condition, and to 1 intervention - of which adaptive stereotactic body radiation therapy (SBRT) with a SIB is the first listed.
NCT07219303 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT07219303 about?
NCT07219303 is a clinical study titled "Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer". The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time. The main questions this trial aims to answer are: * What is highest do...
What is the current status of trial NCT07219303?
This trial is currently recruiting. It is a NA study. The enrollment target is 80 participants. The study started on 2025-09-25. Estimated completion is 2033-11-01.
What conditions does trial NCT07219303 study?
This clinical trial studies the following conditions: Prostate Cancer (Adenocarcinoma).
What interventions are being tested in trial NCT07219303?
The interventions under investigation include: adaptive stereotactic body radiation therapy (SBRT) with a SIB (RADIATION).
Who is sponsoring clinical trial NCT07219303?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219303 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer (Adenocarcinoma)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07219303's enrollment target sits among peer trials
80 5th of 13 higher than 9 of 13 other Prostate Cancer (Adenocarcinoma) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer (Adenocarcinoma) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PSMA PET for Surveillance After Focal Therapy
RECRUITING · NA
-
Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer
RECRUITING · Phase 1
-
FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
RECRUITING · Phase 2
-
A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
RECRUITING · Phase 1
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
RECRUITING
-
Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI